Global Rheumatoid Arthritis Drugs Market Is Expected To Reach Around USD 30.7 Billion By 2025

Zion Market Research has published a new report titled “Rheumatoid Arthritis Drugs Market by Drug Type (NSAID’s, Analgesics, DMARD’s, Glucocorticoids, Biologics, and Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global rheumatoid arthritis drugs market was valued at approximately USD 22.6 billion in 2018 and is expected to generate around USD 30.7 billion by 2025, at a CAGR of 4.5% between 2019 and 2025.

Browse the full “Rheumatoid Arthritis Drugs Market by Drug Type (NSAID’s, Analgesics, DMARD’s, Glucocorticoids, Biologics, and Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/rheumatoid-arthritis-drugs-market

Rheumatoid arthritis (RA) is an autoimmune disorder that leads to pain and inflammation of the joints. It usually affects the joints of wrists, elbows, hands, ankles, and knees. The presence of biologics and biosimilars, the rising prevalence of the disease, and established regulatory guidelines are likely to boost the rheumatoid arthritis drugs market growth globally. Generally, RA affects twice the number of women as compared to men. The rising disease remittance therapies awareness and increasing healthcare expenditure in developed countries are likely to further promote rheumatoid arthritis drugs market growth globally in the future.

The global rheumatoid arthritis drugs market is segmented on the basis of drug type and distribution channel. Based on drug type, the market for rheumatoid arthritis drugs is classified into NSAID’s, analgesics, DMARD’s, glucocorticoids, biologics, and others. The biologics segment further includes TNF-α antagonists, T-cell inhibitors, CD20 antigen, JAK inhibitors, and anti-IL6 biologics. Low prices, availability, and positive results are driving the growth of the biologics segment, particularly in the emerging economies. With the introduction of novel biosimilars, the market for rheumatoid arthritis drugs in the future is poised to create a significant shift in the prescription patterns.

On the basis of the distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, drug stores, and online sales. In recent times, there have been a shift in patients preferring prescription drugs over the OTC (over the counter) drugs, owing to the growing awareness regarding new disease reversal treatment options. Hospital pharmacies are anticipated to dominate the RA drugs market in the future, owing to the rising rheumatologist consultations in hospitals and clinics. The prolonged use of RA medication can lead to drug resistance, which compels the patients to refer to a rheumatologist and follow guided therapies. Additionally, the number of OTC drugs available for treatment is insufficient, which, in turn, is further propelling the growth of this segment.

By region, North America is likely to dominate the rheumatoid arthritis drugs market globally in the future. The U.S. is at the forefront in terms of growth in this region. The rheumatoid arthritis drugs market in the Asia Pacific region is estimated to witness a high growth rate in the years ahead, owing to the rising healthcare expenditure and low manufacturing costs in India and China have resulted in the rise of production facilities which is attracting more pharmaceutical and biotechnological key players to this region.

Some leading players of the global rheumatoid arthritis drugs market include Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Amgen, Inc., UCB S.A., Pfizer, Inc., Bristol-Myers Squibb, AbbVie, F. Hoffmann-La Roche AG, and Novartis International AG.

This report segments the global rheumatoid arthritis drugs market into:

Global Rheumatoid Arthritis Drugs Market: Drug Type Analysis

• NSAID’s
• Analgesics
• DMARD’s
• Glucocorticoids
• Biologics
  • TNF-α Antagonists
  • T-Cell Inhibitors
  • CD20 Antigen
  • JAK Inhibitors
  • Anti-IL6 Biologics
• Others

Global Rheumatoid Arthritis Drugs Market: Distribution Channel Analysis

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Sales

Global Rheumatoid Arthritis Drugs Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com